Have a feature idea you'd love to see implemented?
Let us know!
IONS Ionis Pharmaceuticals Inc
Price (delayed)
$37.81
Market cap
$5.53B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.52
Enterprise value
$6.68B
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and
Highlights
IONS's revenue is up by 29% YoY and by 4.7% QoQ
The gross profit is up by 29% year-on-year and by 4.6% since the previous quarter
The net income has declined by 18% year-on-year but it has increased by 4.9% since the previous quarter
Ionis Pharmaceuticals's EPS has decreased by 16% YoY but it has increased by 6% QoQ
The company's equity fell by 38% YoY and by 11% QoQ
IONS's quick ratio is down by 18% year-on-year
Key stats
What are the main financial stats of IONS
Market
Valuations
Earnings
Shares outstanding
146.21M
Market cap
$5.53B
Enterprise value
$6.68B
Price to book (P/B)
20.93
Price to sales (P/S)
6.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.21
Revenue
$813.46M
EBIT
-$263.22M
EBITDA
-$240.79M
Free cash flow
-$358M
Per share
Balance sheet
Liquidity
EPS
-$2.52
Free cash flow per share
-$2.45
Book value per share
$1.81
Revenue per share
$5.57
TBVPS
$18.44
Total assets
$2.69B
Total liabilities
$2.43B
Debt
$1.44B
Equity
$263.7M
Working capital
$2.02B
Debt to equity
5.47
Current ratio
7.61
Quick ratio
6.88
Net debt/EBITDA
-4.77
Margins
Efficiency
Dividend
EBITDA margin
-29.6%
Gross margin
98.6%
Net margin
-45%
Operating margin
-44.9%
Return on assets
-12.9%
Return on equity
-115.9%
Return on invested capital
-7.4%
Return on capital employed
-11%
Return on sales
-32.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IONS stock price
How has the Ionis Pharmaceuticals stock price performed over time
Intraday
-3.99%
1 week
-8%
1 month
-20.08%
1 year
-12.86%
YTD
-25.26%
QTD
-5.62%
Financial performance
How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$813.46M
Gross profit
$801.89M
Operating income
-$364.99M
Net income
-$365.74M
Gross margin
98.6%
Net margin
-45%
The operating margin is up by 40% year-on-year and by 10% since the previous quarter
IONS's revenue is up by 29% YoY and by 4.7% QoQ
The gross profit is up by 29% year-on-year and by 4.6% since the previous quarter
IONS's operating income is up by 23% year-on-year and by 6% since the previous quarter
Growth
What is Ionis Pharmaceuticals's growth rate over time
Valuation
What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
20.93
P/S
6.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.21
Ionis Pharmaceuticals's EPS has decreased by 16% YoY but it has increased by 6% QoQ
The stock's price to book (P/B) is 87% more than its 5-year quarterly average of 11.2 but 4% less than its last 4 quarters average of 21.8
The company's equity fell by 38% YoY and by 11% QoQ
IONS's revenue is up by 29% YoY and by 4.7% QoQ
The P/S is 25% less than the last 4 quarters average of 9.1 and 16% less than the 5-year quarterly average of 8.1
Efficiency
How efficient is Ionis Pharmaceuticals business performance
IONS's return on equity has dropped by 95% year-on-year and by 7% since the previous quarter
Ionis Pharmaceuticals's return on sales has increased by 15% YoY and by 9% QoQ
IONS's return on assets is down by 13% year-on-year but it is up by 2.3% since the previous quarter
Ionis Pharmaceuticals's ROIC has decreased by 6% YoY but it has increased by 3.9% from the previous quarter
Dividends
What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IONS.
Financial health
How did Ionis Pharmaceuticals financials performed over time
The total assets is 11% greater than the total liabilities
IONS's quick ratio is down by 18% year-on-year
The current ratio has declined by 16% year-on-year but it rose by 3.3% since the previous quarter
Ionis Pharmaceuticals's debt to equity has soared by 57% YoY and by 12% from the previous quarter
The company's equity fell by 38% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.